Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2022-02-14 00:00:00 ET · period of report 2022-02-10 · accession 0001725160-22-000031 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-14 | 2022-02-10 | ZNTL | SUN ANTHONY Y | Pres, CEO, Dir | A - Grant | $0.00 | +50.4K | 1.22M | +4% | $0 |
| DM | 2022-02-14 | 2022-02-14 | ZNTL | SUN ANTHONY Y | Pres, CEO, Dir | S - Sale | $50.23 | -4,733 | 1.22M | -0.4% | -$237.7K |
| D | 2022-02-14 | 2022-02-10 | ZNTL | SUN ANTHONY Y | Pres, CEO, Dir | A - Grant | $0.00 | +118.3K | 118.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-10 | A | A | 50,431 | $0.00 | 1,222,206 | D | — | — | (F1) Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. |
| 2 | Common | Common Stock | 2022-02-14 | S | D | 4,208 | $50.16 | 1,217,998 | D | — | — | (F3) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2022-02-14 | S | D | 525 | $50.75 | 1,217,473 | D | — | — | (F4) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Derivative | Stock Option (Right to Buy) | 2022-02-10 | A | A | 118,319 | $0.00 | 118,319 | D | $52.61 · — to 2032-02-09 | 118,319 Common Stock | (F7) The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. |